Humana (NYSE:HUM) Cut to Hold at Wall Street Zen

Wall Street Zen lowered shares of Humana (NYSE:HUM) from a buy rating to a hold rating in a research report sent to investors on Saturday morning.

Other equities analysts have also recently issued reports about the stock. Mizuho upped their target price on shares of Humana from $305.00 to $316.00 and gave the company an “outperform” rating in a research note on Wednesday, April 9th. Guggenheim began coverage on shares of Humana in a research note on Wednesday, April 9th. They issued a “buy” rating and a $326.00 price objective for the company. Truist Financial lowered their target price on shares of Humana from $280.00 to $260.00 and set a “hold” rating on the stock in a report on Wednesday, July 16th. Barclays set a $275.00 target price on shares of Humana and gave the stock an “equal weight” rating in a research report on Thursday. Finally, Morgan Stanley reduced their target price on shares of Humana from $290.00 to $277.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 31st. Seventeen research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $281.62.

Humana Price Performance

NYSE HUM opened at $247.07 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The company has a fifty day simple moving average of $235.53 and a 200 day simple moving average of $254.67. The company has a market cap of $29.72 billion, a P/E ratio of 18.96, a P/E/G ratio of 1.45 and a beta of 0.44. Humana has a 1 year low of $206.87 and a 1 year high of $382.72.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). The firm had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%. Humana’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the company posted $6.96 earnings per share. On average, sell-side analysts predict that Humana will post 16.47 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in HUM. Cary Street Partners Investment Advisory LLC increased its stake in shares of Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after buying an additional 46 shares during the period. Riverview Trust Co acquired a new position in shares of Humana in the first quarter valued at approximately $34,000. Garde Capital Inc. acquired a new position in shares of Humana in the first quarter valued at approximately $36,000. Zions Bancorporation National Association UT acquired a new position in shares of Humana in the first quarter valued at approximately $37,000. Finally, Transce3nd LLC acquired a new position in shares of Humana in the fourth quarter valued at approximately $38,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.